Interaksi Deferipron

Deferipron (Ferriprox), golongan suplemen zat besi, memiliki 28 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 7 mayor, 16 moderat, 5 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (7)

  • DiklofenakOAINSMayor

    Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (label Deferipron, Interaksi obat)

  • Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (label Deferipron, Interaksi obat)

  • MetildopaantihipertensiMayor

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (label Metildopa, Interaksi obat)

  • Milk thistle (silimarin)Herbal dan suplemenMayor

    Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (label Deferipron, Interaksi obat)

  • Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (label Deferipron, Interaksi obat)

  • Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (label Deferipron, Interaksi obat)

  • RisedronatbisfosfonatMayor

    Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (label Risedronat, Interaksi obat)

Interaksi moderat (16)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (label Deferipron, Interaksi obat)

  • Dekslansoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Dekslansoprazol, Interaksi obat)

  • Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitamins cation-containing antacids or laxatives sucralfate buffered medications ↓ elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

  • Esomeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (label Esomeprazol, Interaksi obat)

  • KarbidopaModerat

    Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. (label Karbidopa, Interaksi obat)

  • Karbidopa dan levodopaobat dopaminergikModerat

    Dopamine D2 receptor antagonists, isoniazid, iron salts, and high-protein diet may reduce the effectiveness of DUOPA ( 7.3 , 7.4 , 7.5 ) (label Karbidopa dan levodopa, Interaksi obat)

  • Karbidopa, levodopa, dan entakaponobat dopaminergikModerat

    • Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

  • Lansoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Lansoprazol, Interaksi obat)

  • Levodopaobat dopaminergikModerat

    Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2 , 7.3 ) (label Levodopa, Interaksi obat)

  • Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, mycophenoloate mofetil, ketoconazole) Clinical Impact: Esomeprazole magnesium can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole magnesium is an enantiomer,… (label Naproksen dan esomeprazol, Interaksi obat)

  • Natrium bikarbonatantasidaModerat

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (label Deferipron, Interaksi obat)

  • Omeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Omeprazol, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (label Deferipron, Interaksi obat)

  • Pantoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Pantoprazol, Interaksi obat)

  • Rabeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Rabeprazol, Interaksi obat)

  • SefdinirsefalosporinModerat

    Iron Supplements and Foods Fortified With Iron: Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO 4 ) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. (label Sefdinir, Interaksi obat)

Penyebutan minor (5)

  • Oral medications or supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives Sucralfate Buffered medications ↓ bictegravir Antacids containing Al/Mg : Take BIXLENVO at least 2 hours before or 6 hours after taking antacids containing Al/Mg. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

  • Demeklosiklinantibiotik tetrasiklinMinor

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations. (label Demeklosiklin, Interaksi obat)

  • Doksisiklinantibiotik tetrasiklinMinor

    Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. (label Doksisiklin, Interaksi obat)

  • DolutegravirantiretroviralMinor

    Oral calcium or iron supplements, including multivitamins containing calcium or iron a ↓Dolutegravir When taken with food, TIVICAY and supplements or multivitamins containing calcium or iron can be taken at the same time. (label Dolutegravir, Interaksi obat)

  • Minosiklinantibiotik tetrasiklinMinor

    Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (label Minosiklin, Interaksi obat)

Periksa Deferipron terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.